305 related articles for article (PubMed ID: 28277882)
1. Investigational therapies for squamous cell lung cancer: from animal studies to phase II trials.
Shum E; Wang F; Kim S; Perez-Soler R; Cheng H
Expert Opin Investig Drugs; 2017 Apr; 26(4):415-426. PubMed ID: 28277882
[TBL] [Abstract][Full Text] [Related]
2. Emerging drugs for squamous cell lung cancer.
Cheng H; Shcherba M; Kandavelou K; Liang Y; Liu H; Perez-Soler R
Expert Opin Emerg Drugs; 2015 Mar; 20(1):149-60. PubMed ID: 25557559
[TBL] [Abstract][Full Text] [Related]
3. Best practice in the treatment of advanced squamous cell lung cancer.
Ang YL; Tan HL; Soo RA
Ther Adv Respir Dis; 2015 Oct; 9(5):224-35. PubMed ID: 25902866
[TBL] [Abstract][Full Text] [Related]
4. Second-line therapy of squamous non-small cell lung cancer: an evolving landscape.
Lazzari C; Karachaliou N; Gregorc V; Bulotta A; Gonzalez-Cao M; Verlicchi A; Altavilla G; Rosell R; Santarpia M
Expert Rev Respir Med; 2017 Jun; 11(6):469-479. PubMed ID: 28467720
[TBL] [Abstract][Full Text] [Related]
5. Investigational drugs for treating anal cancer and future perspectives.
Bustamante L; Frakes J; Hoffe S; Kim R
Expert Opin Investig Drugs; 2016; 25(1):51-62. PubMed ID: 26560877
[TBL] [Abstract][Full Text] [Related]
6. Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer.
Rijavec E; Genova C; Barletta G; Biello F; Rossi G; Tagliamento M; Dal Bello MG; Coco S; Vanni I; Boccardo S; Alama A; Grossi F
Expert Opin Investig Drugs; 2017 May; 26(5):551-561. PubMed ID: 28388262
[TBL] [Abstract][Full Text] [Related]
7. Investigational drugs for the treatment of cervical cancer.
Barra F; Lorusso D; Leone Roberti Maggiore U; Ditto A; Bogani G; Raspagliesi F; Ferrero S
Expert Opin Investig Drugs; 2017 Apr; 26(4):389-402. PubMed ID: 28274154
[TBL] [Abstract][Full Text] [Related]
8. Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma.
Guazzelli A; Bakker E; Tian K; Demonacos C; Krstic-Demonacos M; Mutti L
Expert Opin Investig Drugs; 2017 Aug; 26(8):933-944. PubMed ID: 28679291
[TBL] [Abstract][Full Text] [Related]
9. Innovative Clinical Trials: The LUNG-MAP Study.
Steuer CE; Papadimitrakopoulou V; Herbst RS; Redman MW; Hirsch FR; Mack PC; Ramalingam SS; Gandara DR
Clin Pharmacol Ther; 2015 May; 97(5):488-91. PubMed ID: 25676724
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy for small-cell lung cancer: emerging evidence.
Reck M; Heigener D; Reinmuth N
Future Oncol; 2016 Apr; 12(7):931-43. PubMed ID: 26882955
[TBL] [Abstract][Full Text] [Related]
11. Investigational therapies in phase II clinical trials for the treatment of soft tissue sarcoma.
Martin-Liberal J; Pérez E; García Del Muro X
Expert Opin Investig Drugs; 2019 Jan; 28(1):39-50. PubMed ID: 30513001
[TBL] [Abstract][Full Text] [Related]
12. Emerging therapeutic agents for advanced non-small cell lung cancer.
Chen R; Manochakian R; James L; Azzouqa AG; Shi H; Zhang Y; Zhao Y; Zhou K; Lou Y
J Hematol Oncol; 2020 May; 13(1):58. PubMed ID: 32448366
[TBL] [Abstract][Full Text] [Related]
13. Investigational drugs for nasopharyngeal carcinoma.
Ma BBY; Hui EP; Chan ATC
Expert Opin Investig Drugs; 2017 Jun; 26(6):677-685. PubMed ID: 28446055
[TBL] [Abstract][Full Text] [Related]
14. Understanding immunotherapy for the treatment of non-small cell lung cancer.
Thomas R
Br J Nurs; 2016 Sep; 25(16):S12-7. PubMed ID: 27615536
[TBL] [Abstract][Full Text] [Related]
15. Emerging drugs targeting PD-1 and PD-L1: reality or hope?
Casaluce F; Sgambato A; Sacco PC; Palazzolo G; Maione P; Rossi A; Ciardiello F; Gridelli C
Expert Opin Emerg Drugs; 2014 Dec; 19(4):557-69. PubMed ID: 25253438
[TBL] [Abstract][Full Text] [Related]
16. The safety of second-line treatment options for non-small cell lung cancer.
Rossi A; Maione P; Santabarbara G; Sacco PC; Casaluce F; Sgambato A; Barzelloni ML; Palazzolo G; Gridelli C
Expert Opin Drug Saf; 2017 Apr; 16(4):471-479. PubMed ID: 28276858
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in squamous non-small cell lung cancer: evidence beyond predictive biomarkers.
Genova C; Rijavec E; Grossi F
Expert Rev Anticancer Ther; 2016; 16(1):1-4. PubMed ID: 26567561
[TBL] [Abstract][Full Text] [Related]
18. Squamous cell lung cancer: from tumor genomics to cancer therapeutics.
Gandara DR; Hammerman PS; Sos ML; Lara PN; Hirsch FR
Clin Cancer Res; 2015 May; 21(10):2236-43. PubMed ID: 25979930
[TBL] [Abstract][Full Text] [Related]
19. Novel therapies for advanced squamous cell carcinoma of the lung.
Koutsoukos K; Mountzios G
Future Oncol; 2016 Mar; 12(5):659-67. PubMed ID: 26880383
[TBL] [Abstract][Full Text] [Related]
20. Second-line treatments of small-cell lung cancers.
Baize N; Monnet I; Greillier L; Quere G; Kerjouan M; Janicot H; Vergnenegre A; Auliac JB; Chouaid C
Expert Rev Anticancer Ther; 2017 Nov; 17(11):1033-1043. PubMed ID: 28849951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
